Viktoria Ekström-Rydén
PhD student at Department of Immunology, Genetics and Pathology; Research programme: Cancer Immunotherapy; Research group Gustav Ullenhag
- E-mail:
- viktoria.ekstrom-ryden@igp.uu.se
- Visiting address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala - Postal address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
Publications
Recent publications
-
Part of Nature Communications, 2026
- DOI for LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial
- Download full text (pdf) of LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial
-
Part of ESMO Open, 2026
- DOI for First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies
- Download full text (pdf) of First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies
-
Part of Biomarker Research, 2026
- DOI for Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients
- Download full text (pdf) of Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients
-
Part of Cancer Immunology and Immunotherapy, 2025
- DOI for Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
- Download full text (pdf) of Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
-
Part of Frontiers in Oncology, 2024
- DOI for Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
- Download full text (pdf) of Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
All publications
Articles in journal
-
Part of Nature Communications, 2026
- DOI for LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial
- Download full text (pdf) of LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial
-
Part of ESMO Open, 2026
- DOI for First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies
- Download full text (pdf) of First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies
-
Part of Biomarker Research, 2026
- DOI for Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients
- Download full text (pdf) of Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients
-
Part of Cancer Immunology and Immunotherapy, 2025
- DOI for Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
- Download full text (pdf) of Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
-
Part of Frontiers in Oncology, 2024
- DOI for Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
- Download full text (pdf) of Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
-
Part of Pigment Cell & Melanoma Research, 2024
- DOI for The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
- Download full text (pdf) of The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
-
Part of Cancer Medicine, p. 13217-13224, 2023
- DOI for Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study
- Download full text (pdf) of Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study